Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analytic methodology
PubMed 37400359 · doi:10.1111/nyas.15012
What was done
The authors synthesized literature on nonalcoholic fatty liver disease (NAFLD), summarizing its risk factors, natural history across the clinicopathologic spectrum (from nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis), diagnostic considerations, and current clinical management approaches.
What was found
The abstract reports no primary experimental or observational trial data. It notes predictive modeling forecasts indicating that over 100 million adults in the United States (representing more than one-third of the population) will have NAFLD by 2030, and identifies NAFLD as a leading indication for liver transplantation in the US.
Why it matters
This review provides an overview of the escalating public health burden of NAFLD and outlines the broad clinical spectrum of hepatic and extra-hepatic outcomes.
Limits
As a narrative overview, this paper provides no primary empirical data, systematic methodology, or quantitative effect sizes. Numerical figures in the abstract rely entirely on secondary predictive models rather than direct trial or cohort measurements.
Cited by
- context Fructose is causing chronic liver disease in approximately 100 million Americans.